| Literature DB >> 29102593 |
Xinxin Wang1, Shanshan Ma2, Bo Yang3, Tuanjie Huang2, Nan Meng4, Ling Xu2, Qu Xing2, Yanting Zhang2, Kun Zhang2, Qinghua Li2, Tao Zhang2, Junwei Wu4, Greta Luyuan Yang5, Fangxia Guan6, Jian Wang7.
Abstract
Mesenchymal stem cell transplantation is a promising therapeutic approach for Alzheimer's disease (AD). However, poor engraftment and limited survival rates are major obstacles for its clinical application. Resveratrol, an activator of silent information regulator 2, homolog 1 (SIRT1), regulates cell destiny and is beneficial for neurodegenerative disorders. The present study is designed to explore whether resveratrol regulates the fate of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and whether hUC-MSCs combined with resveratrol would be efficacious in the treatment of neurodegeneration in a mouse model of AD through SIRT1 signaling. Herein, we report that resveratrol facilitates hUC-MSCs engraftment in the hippocampus of AD mice and resveratrol enhances the therapeutic effects of hUC-MSCs in this model as demonstrated by improved learning and memory in the Morris water maze, enhanced neurogenesis and alleviated neural apoptosis in the hippocampus of the AD mice. Moreover, hUC-MSCs and resveratrol jointly regulate expression of hippocampal SIRT1, PCNA, p53, ac-p53, p21, and p16. These data strongly suggests that hUC-MSCs transplantation combined with resveratrol may be an effective therapy for AD.Entities:
Keywords: Alzheimer's disease; Human umbilical cord-derived mesenchymal stem cells; Resveratrol, SIRT1; Transgenic mice
Mesh:
Substances:
Year: 2017 PMID: 29102593 PMCID: PMC5729114 DOI: 10.1016/j.bbr.2017.10.032
Source DB: PubMed Journal: Behav Brain Res ISSN: 0166-4328 Impact factor: 3.332